Health
Finerenone limits AFib in patients with chronic kidney disease, Type 2 diabetes – Cardiovascular Business
Treatment with finerenone can help limit new-onset atrial fibrillation (AFib) among patients with chronic kidney disease (CKD) and Type 2 diabetes (T2D), according to new data presented at ACC.21, the American College of Cardiologys 70th annual scientific session.
In the FIDELIO-DKD trial, researchers had already concluded that finerenone, a mineralocorticoid receptor antagonist, reduces the risk of cardiovascular complications in patients with CKD and T2D. This secondary analysis of that same data…
Continue Reading
-
General6 hours agoAlbanese beats drum on economy as trade clouds gather
-
General5 hours agoToo skewed, too gentlemanly | The Spectator Australia
-
Business3 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher
-
General4 hours agoHow a fake expert crashed the World | The West Report